Consultancy Services are provided:-
... to accelerate the development and commercialisation of life science and pharmaceutical businesses and products.
Services include:-
... to accelerate the development and commercialisation of life science and pharmaceutical businesses and products.
Services include:-
- strategic, management, and project leadership,
- product development including integration of regulatory and intellectual property strategies,
- linkages to development, manufacturing and commercialisation partners,
- networks of relevant international experts,
- due diligence and assessment on new product and business acquisitions.
Some of the Clients & Partners include:-
Biopharmaceutical company (US)
Biopharmaceutical company (US)
- A company with a turnover ~ US$ 1bn
- Development of an IP defence strategy in advance of an imminent generic competitor launch
- A company with a turnover ~ US$ 100m
- Assessment of current product development portfolio
- Recommendations on future development strategy and opportunities
- A top 10 global generic pharmaceutical company
- Product development and commercialisation strategies for a range of oral oncology products
- Assistance with API, formulation, intellectual property, and regulatory strategies; together with commercial partnering and capital raising
- A company that develops and acquires generic and branded products for distribution in international markets
- Assistance with product development and commercialisation strategies for an injectable oncology product, including sourcing API and a contract development and manufacturing partner.
- Due Diligence on a veterinary pharmaceutical business seeking private equity so as to expand into global markets with its specialist products developed and manufactured in Australia
- Due Diligence on a generic pharmaceutical business seeking private equity to expand it's existing global generic product portfolio and contract manufacturing business
- Review and recommendations regarding the skills, function and structure of the R&D organisation
- Market Capital ~ US$ 300m
- Development and manufacture of oral oncology APIs and finished dose forms
- Development and manufacture of injectable oncology finished dose forms
For further information on consultancy services
Please contact me - refer to Contact.
Please contact me - refer to Contact.